Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

FDA and BD identify chemical interference with lead tests performed on whole blood samples by Magellan gear

Published 03/22/2018, 03:32 PM
© Reuters. FDA and BD identify chemical interference with lead tests performed on whole blood samples by Magellan gear
  • Becton, Dickinson & Company, at the FDA's request, has identified the source of false results from lead tests performed on whole blood samples collected in Vacutainer tubes on equipment made by Meridian Bioscience (VIVO) unit Magellan Diagnostics.
  • The culprit appears to be a chemical called thiuram which is used to make certain rubber stoppers placed in the tubes after the blood is collected. Thiuram releases gases that contain sulfur which dissolve in blood samples and tightly bind to lead particles. The chemical reaction interferes with the ability of Magellan's test to accurately measure the amount of lead.
  • The FDA maintains its recommendation not to use Magellan's lead tests with venous blood samples. Tests performed on finger/heel-stick samples (capillary samples) are unaffected.
  • Previously: Meridian unit Magellan in hot water with FDA over lead test results (July 13, 2017)
  • Previously: Becton, Dickinson gets Warning Letter after FDA inspection of New Jersey facility (Jan. 11)
  • Now read: Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/22/2018)


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.